| Not Yet Recruiting | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer NCT06196671 | Fudan University | Phase 2 |
| Not Yet Recruiting | Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening NCT07513116 | M.D. Anderson Cancer Center | N/A |
| Not Yet Recruiting | Impact of Hypertrophy-oriented Resistance Training on Muscle Mass and Quality of Life in Patients With Unresec NCT07470268 | Universidad Europea de Madrid | N/A |
| Not Yet Recruiting | Study of Perioperative NP137 and FOLFIRINOX in Resectable Pancreatic Cancer NCT06203821 | Aram Hezel | Phase 1 |
| Not Yet Recruiting | Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer NCT07377526 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Not Yet Recruiting | Assessment of Adherence to Remotely Monitored Physical Activity Tracked on a Smartwatch, and Its Impact on Red NCT07429487 | Centre Antoine Lacassagne | N/A |
| Not Yet Recruiting | Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma NCT07529808 | BigHat Biosciences, Inc. | Phase 1 / Phase 2 |
| Suspended | Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC NCT05494697 | AIM ImmunoTech Inc. | Phase 2 |
| Not Yet Recruiting | e-Health Psychosocial Stress and Symptom Management (ePSMI) for Pancreatic Cancer Patients NCT06893276 | University of Miami | N/A |
| Not Yet Recruiting | ANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pa NCT07444541 | Anova Innovation Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors NCT07360119 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | N/A |
| Not Yet Recruiting | Ambispective Validation of the Odesa Criteria 2026 (OC26): A Flexible Point-Based System for Diagnosis of Auto NCT07536841 | Military Medical Clinical Center of the Southern Region, Ukraine | — |
| Not Yet Recruiting | Phase 1/2a Study of RP-001 in Participants With Advanced Malignancies NCT07504263 | Recurv Pharma Inc | Phase 1 / Phase 2 |
| Recruiting | Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma NCT07126158 | Washington University School of Medicine | Phase 2 |
| Not Yet Recruiting | Endoscopic Management of Biliopancreatic Disease in the Lombardy Pancreas Units NCT07418164 | IRCCS San Raffaele | — |
| Not Yet Recruiting | Chemotherapy With or Without IMD10 (Focused Ultrasound) in the Treatment of Borderline Resectable or Locally A NCT07325214 | IMGT Co., Ltd. | N/A |
| Recruiting | KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer NCT07353645 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 1 / Phase 2 |
| Not Yet Recruiting | PAN-CLO-BU (PANcreas-CLOstridium-BUtyricum) NCT07422103 | Casa di Cura Dott. Pederzoli | N/A |
| Recruiting | Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Ad NCT07491445 | Revolution Medicines, Inc. | Phase 3 |
| Not Yet Recruiting | Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat i NCT07488884 | ImmunityBio, Inc. | Phase 1 |
| Recruiting | AI-Powered Precision Decision-Making for Pancreatic Diseases NCT07439757 | Changhai Hospital | — |
| Not Yet Recruiting | Simulation-Free Celiac Plexus Pain Ablation Using Stereotactic Body Radiotherapy (SBRT) in Participants With C NCT07117032 | Case Comprehensive Cancer Center | Phase 1 |
| Not Yet Recruiting | EUS-guided CTCs + Multi-omics: Predicting Pancreatic Cancer Recurrence and Metastases NCT07448376 | Huazhong University of Science and Technology | — |
| Not Yet Recruiting | A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer NCT07383922 | FutureGen Biopharmaceutical (Beijing) Co., Ltd | Phase 3 |
| Recruiting | A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX C NCT07409272 | Astellas Pharma Global Development, Inc. | Phase 3 |
| Recruiting | CAR-NK Cells (CL-NK-003) in Pancreatic Cancer NCT07425483 | Changhai Hospital | Phase 1 |
| Recruiting | Cancer Loyalty Card Study 2 (CLOCS-2) NCT06447064 | Imperial College London | — |
| Recruiting | B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Differe NCT07236177 | Poitiers University Hospital | EARLY_Phase 1 |
| Not Yet Recruiting | Mainstreaming Genetics: Evaluation of a Digital Application to Scale and Spread Oncologist-initiated Genetic T NCT07387263 | Unity Health Toronto | N/A |
| Not Yet Recruiting | IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer NCT07415525 | Zhejiang University | Phase 2 |
| Not Yet Recruiting | Comparison of Transmesocolic Versus Retromesenteric Reconstruction in Cephalic Duodenopancreatectomy (FAST Tri NCT07368218 | Hospital Universitari de Bellvitge | N/A |
| Recruiting | Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients With Pancreatic NCT07254091 | Northwell Health | EARLY_Phase 1 |
| Recruiting | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors NCT07349537 | Revolution Medicines, Inc. | Phase 1 |
| Recruiting | Feasibility Study of Suizenji, in Patients With Unresectable Pancreatic Ductal Adenocarcinoma (SUNRISE-II) NCT07033689 | SONIRE Therapeutics Inc. | EARLY_Phase 1 |
| Not Yet Recruiting | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Advanced Pancreatic Cancer NCT06755359 | Alpha Tau Medical LTD. | N/A |
| Withdrawn | Feasibility Study of LUM Imaging System for Pancreatic Cancer NCT04276909 | Lumicell, Inc. | N/A |
| Not Yet Recruiting | Hepatobiliary and Pancreatic Tumor Biobank NCT07344116 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Not Yet Recruiting | Active Anti-diabetic Treatment Plus Chemotherapy for Pancreatic Cancer Related Diabetes NCT07272109 | Fudan University | Phase 3 |
| Enrolling By Invitation | Metastatic Non-Familial Adenocarcinoma Maintenance Therapy With DZ-002: Heptamine Carboxymethine Dye Conjugate NCT07344220 | Hoag Memorial Hospital Presbyterian | Phase 2 |
| Recruiting | Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) NCT07252232 | Revolution Medicines, Inc. | Phase 3 |
| Recruiting | Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer Emitters for the Treatment of Locally A NCT06026943 | Alpha Tau Medical LTD. | N/A |
| Not Yet Recruiting | Observational Copenhagen Pancreatic Cancer Study NCT06713525 | Inna Chen, MD | — |
| Not Yet Recruiting | Adebrelimab Combined With Chemotherapy for Neoadjuvant Therapy in Resectable Pancreatic Cancer NCT06177522 | Jinling Hospital, China | Phase 2 |
| Recruiting | A Study of Multiparametric Ultrasound Imaging Methods NCT07270237 | Memorial Sloan Kettering Cancer Center | N/A |
| Recruiting | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors NCT07300150 | PAQ Therapeutics, Inc. | Phase 1 |
| Recruiting | Research of the Application of Pancreatic Cancer Screening Artificial Intelligence Model "PANDAPro" NCT06643715 | Zhejiang University | N/A |
| Recruiting | The Role of Microbiota in Pancreatic Cancer and Precursor Lesions NCT07250100 | Herlev Hospital | — |
| Recruiting | Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2) NCT07243262 | Imperial College London | — |
| Recruiting | Clinical Study of 177Lu-CTR-FAPI In the Treatment of Patients With Advanced, Metastatic Solid Tumors NCT07229768 | Yan Xing | EARLY_Phase 1 |
| Not Yet Recruiting | AG Followed by FOLFIRINOX Both Combined With PD-L1 Antibodies as a Conversion Therapy for Borderline Resectabl NCT07208539 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | A First-in-Human Study of FID-022 in Solid Tumor Patients NCT07249775 | H. Lee Moffitt Cancer Center and Research Institute | — |
| Not Yet Recruiting | In-Depth Characterisation of Biliary Strictures and Hepato-Pancreato-Biliary Focal Lesions for Development of NCT07206355 | University of Nottingham | — |
| Not Yet Recruiting | Stereotactic Body Radiotherapy and NALIRIFOX for Locally Advanced Pancreatic Cancer: A Prospective Clinical Tr NCT07173387 | Shandong Cancer Hospital and Institute | Phase 2 |
| Not Yet Recruiting | MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer NCT07132060 | Clinica Universidad de Navarra, Universidad de Navarra | N/A |
| Not Yet Recruiting | Clinical Application of PET Imaging Targeting GPA33 in Malignant Tumors NCT07172503 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N/A |
| Not Yet Recruiting | A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusio NCT07055568 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Recruiting | LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study NCT07312422 | Zhejiang Provincial People's Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of PHN-012 in Patients With Advanced Solid Tumors NCT07127874 | Pheon Therapeutics | Phase 1 |
| Recruiting | A Study of AK130 in Combination With AK112 for the Treatment of Advanced Pancreatic Cancer NCT07114315 | Akeso | Phase 2 |
| Recruiting | DESTINY-PANTUMOUR04 NCT07124000 | AstraZeneca | — |
| Recruiting | Tissue Adhesive Glue Modified Cyanoacrylate (Glubran® 2) in Soft Pancreas NCT07155525 | Minia University | Phase 3 |
| Not Yet Recruiting | Stereotactic Centralized Ablative Radiotherapy for Locally Advanced Pancreatic Cancer: A Single-Arm Phase I Sa NCT07173374 | Shandong Cancer Hospital and Institute | Phase 1 |
| Withdrawn | A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With NCT06690281 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Can NCT07079228 | Qilu Pharmaceutical Co., Ltd. | Phase 3 |
| Recruiting | NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metas NCT06941857 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Not Yet Recruiting | Exercise to Boost Immunity in Advanced Cancer NCT06310993 | Sheffield Teaching Hospitals NHS Foundation Trust | N/A |
| Not Yet Recruiting | Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing M NCT06999512 | Assistance Publique - Hôpitaux de Paris | Phase 2 / Phase 3 |
| Not Yet Recruiting | [Ga-68]MTP220 PET for Biodistribution and Efficacy in Pancreatic Cancer and Head and Neck Cancers NCT07026981 | Qiubai Li | EARLY_Phase 1 |
| Not Yet Recruiting | Spanish Registry of Direct Cholangiopancreatoscopy by Single Operator NCT07064447 | Germans Trias i Pujol Hospital | — |
| Recruiting | Clinical Application of PET Imaging Targeting CLDN18.2 in Malignant Tumors NCT07301814 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Not Yet Recruiting | A Phase I/IIa Study of EF-009 in Patients with Pancreatic Cancer NCT04381130 | Everfront Biotech Co., Ltd. | Phase 1 / Phase 2 |
| Enrolling By Invitation | A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Product NCT06885424 | A2 Biotherapeutics Inc. | — |
| Recruiting | HRS-4642 in Combination With Gemcitabine and Albumin-bound Paclitaxel and Adebrelimab for Neoadjuvant and Adju NCT07131514 | Ruijin Hospital | Phase 2 |
| Recruiting | IDOV-Immune for Advanced Solid Tumors NCT06910657 | ViroMissile, Inc. | Phase 1 |
| Recruiting | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors NCT07090499 | Pfizer | Phase 1 |
| Not Yet Recruiting | EUS- and US- Guided Biopsy for Pancreatic Lesion NCT07138976 | Tian'an Jiang | — |
| Not Yet Recruiting | XH001 (New Antigen Tumor Vaccine) Combined With Chemotherapy as Adjuvant Therapy in Pancreatic Cancer NCT07114666 | Peking Union Medical College Hospital | N/A |
| Recruiting | Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer NCT07117045 | Changhai Hospital | — |
| Not Yet Recruiting | Efficacy and Safety of LM-302 Combined With Gemcitabine CLDN 18.2 Positive Unresectable Locally Advanced or Me NCT07108504 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 1 NCT07066098 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 |
| Recruiting | 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer NCT06298916 | Lantheus Medical Imaging | Phase 1 / Phase 2 |
| Recruiting | A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors NCT07066657 | ArriVent BioPharma, Inc. | Phase 1 |
| Recruiting | Sample Collection for Ongoing Research and Product Evaluation Study NCT07318051 | Natera, Inc. | — |
| Recruiting | PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery fo NCT07167264 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Not Yet Recruiting | Efficacy of TEAS on Postoperative Pain and Recovery in Patients Undergoing Pancreatectomy NCT06541561 | West China Hospital | N/A |
| Not Yet Recruiting | A Phase II, EvaluateBLEX 404 Combined With Gemcitabine Monotherapy With Pancreatic Cancer NCT03301805 | Rgene Corporation | Phase 2 |
| Not Yet Recruiting | Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With H NCT06779318 | The First Affiliated Hospital with Nanjing Medical University | Phase 4 |
| Not Yet Recruiting | Surveillance Discontinuation in 5 Year Stable Trivial Branch Duct Intraductal Papillary Mucinous Neoplasms NCT07056972 | Azienda Ospedaliera di Padova | — |
| Recruiting | KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal C NCT06411691 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Recruiting | Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic NCT06698458 | Alpha Tau Medical LTD. | N/A |
| Recruiting | A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer NCT06953999 | Akeso | Phase 3 |
| Completed | ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid Tumors NCT06973161 | AstraZeneca | — |
| Not Yet Recruiting | Proteomic Analysis of Patients Undergoing Bariatric Surgery NCT06787807 | Universidade Federal de Pernambuco | N/A |
| Not Yet Recruiting | Ivonescimab With GnP and SBRT in Patients With Metastatic Pancreatic Cancer (WGOG-PAN 004) NCT06991491 | West China Hospital | Phase 2 |
| Recruiting | Laparoscopic Pancreaticoduodenectomy NCT07009119 | Minia University | N/A |
| Not Yet Recruiting | Predicting Cancer in Pancreatic Cystic Lesions Through Artificial Intelligence NCT06954753 | Centre Hospitalier Universitaire de Nice | — |
| Recruiting | Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectabl NCT06782932 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 / Phase 2 |
| Recruiting | MK2 Inhibitor in Combination With mFOLFIRINOX for Untreated Metastatic Pancreatic Ductal Adenocarcinoma NCT06648434 | Washington University School of Medicine | Phase 1 |
| Recruiting | ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic NCT06801899 | Insel Gruppe AG, University Hospital Bern | N/A |
| Recruiting | EXoPERT EMERALD Clinical Study NCT07186296 | EXoPERT | — |
| Recruiting | EUS-guided Choledochoduodenostomy vs ERCP as First Line in Malignant Distal Obstruction (CARPEDIEM Trial) NCT06653192 | Hospital Universitari de Bellvitge | N/A |
| Not Yet Recruiting | An Exploratory Clinical Study of HRS-4642 in Combination With Immunotherapy and Chemotherapy for Pancreatic Ca NCT06938282 | Shanghai Zhongshan Hospital | Phase 2 |
| Recruiting | Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer NCT07066995 | Essen Biotech | Phase 1 / Phase 2 |
| Recruiting | A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advan NCT07172802 | GI Innovation, Inc. | Phase 1 / Phase 2 |
| Recruiting | A Clinical Study on the First-line Treatment of Metastatic Pancreatic Cancer With TQB2916 Injection Combined W NCT06962267 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Phase 2 |
| Recruiting | PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) NCT06673017 | PanTher Therapeutics | Phase 1 |
| Recruiting | 18F Labeled FAP Targeted Molecular Probe in Early Tumor Diagnosis NCT06937112 | Nanjing First Hospital, Nanjing Medical University | — |
| Recruiting | CAR-NK Cells (CL-NK-001) in Pancreatic Cancer NCT06816823 | Changhai Hospital | Phase 1 |
| Recruiting | A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer NCT06944106 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 |
| Recruiting | A Phase I Clinical Study of IX001 TCR-T Injection in the Treatment of Advanced Pancreatic Cancer Patients With NCT06898385 | Sun Yat-sen University | Phase 1 |
| Recruiting | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chem NCT06758544 | Guangdong Provincial People's Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Single-arm, Open-label Clinical Study to Evaluate the Efficacy and Safety of VRT106 in Combination With Chem NCT06866977 | Xiangya Hospital of Central South University | Phase 1 / Phase 2 |
| Recruiting | Brodalumab in the Treatment of Immune-Related Adverse Events NCT06673329 | Brian Henick, MD | Phase 1 |
| Active Not Recruiting | Progressive Muscle Relaxation Exercises on Sleep, Fatigue and Pain in Pancreatic and Colon Cancer Patients NCT06920082 | Istanbul Sabahattin Zaim University | N/A |
| Recruiting | Pembrolizumab With Olaparib as Combined Therapy in Metastatic Pancreatic Cancer NCT05093231 | Cambridge University Hospitals NHS Foundation Trust | Phase 2 |
| Recruiting | The Characteristics of Oral Microbiota in Chronic Pancreatitis and Autoimmune Pancreatitis NCT07015580 | Ruijin Hospital | — |
| Completed | Clinical Validation of a Blood Biomarker Test to Detect Early-Stage Pancreatic Cancer (VERIFI) NCT06947395 | Immunovia, Inc. | — |
| Recruiting | A Study of GC203 TIL in PDCA (RJ) NCT06828328 | Shanghai Juncell Therapeutics | EARLY_Phase 1 |
| Not Yet Recruiting | The Influence of Secretin Stimulated Pancreatic Secretion on ctDNA Expression in Patients With Pancreatic Duct NCT06807112 | Charles University, Czech Republic | — |
| Recruiting | Adapted Guided Stereotactic Body Radiotherapy Combined with Chemotherapy and Enhancement of Novel Drug Ivonesc NCT06844422 | Shandong Cancer Hospital and Institute | Phase 1 / Phase 2 |
| Recruiting | Onvansertib in Combination With NALIRIFOX for First Line Treatment of Advanced Pancreatic Cancer NCT06736717 | University of Kansas Medical Center | Phase 1 / Phase 2 |
| Recruiting | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) NCT06710132 | EMD Serono Research & Development Institute, Inc. | Phase 1 / Phase 2 |
| Recruiting | Validation of a miRNA Panel to Optimize Treatment Response in Patients With Metastatic Pancreatic Cancer (mirP NCT06945978 | Benedito Mauro Rossi | — |
| Recruiting | A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors NCT06695845 | Jazz Pharmaceuticals | Phase 2 |
| Recruiting | FAPi PET in Pancreatic Ductal Adenocarcinoma NCT07342231 | Tata Memorial Hospital | — |
| Recruiting | Pancreatic Cancer and Diabetes Mellitus NCT06585072 | Shanghai Changzheng Hospital | — |
| Not Yet Recruiting | Validation of Joint-AI in Diagnosing Pancreatic Solid Lesions NCT06753318 | Huazhong University of Science and Technology | N/A |
| Recruiting | The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy NCT06282809 | HistoSonics, Inc. | N/A |
| Recruiting | Target-specific immunoPET Imaging of Digestive System Carcinoma NCT06715839 | RenJi Hospital | N/A |
| Recruiting | HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer NCT06587061 | Ruijin Hospital | Phase 2 |
| Not Yet Recruiting | BGT007 Treatment for Recurrent/refractory Gastrointestinal Malignancies NCT06645301 | BioSyngen Pte Ltd | EARLY_Phase 1 |
| Recruiting | Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer NCT06601283 | Fudan University | Phase 2 / Phase 3 |
| Recruiting | Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer NCT06598033 | Fudan University | Phase 2 / Phase 3 |
| Not Yet Recruiting | Second-line Irinotecan Liposome Combination Regimen for Irinotecan-treated Pancreatic Cancer NCT06700603 | Rui-hua Xu, MD, PhD | Phase 2 |
| Active Not Recruiting | The Effect of Celiac Axis Stenosis on Morbidity After Pancreatoduodenectomy - A Prospective Study NCT07412301 | Larissa University Hospital | — |
| Recruiting | Namodenoson Treatment of Advanced Pancreatic Cancer NCT06387342 | Can-Fite BioPharma | Phase 2 |
| Not Yet Recruiting | Irreversible Electroporation Ablation Combined With Anti-PD(L)1 Therapy for Locally Advanced Pancreatic Cancer NCT06677762 | Ruijin Hospital | — |
| Recruiting | Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer NCT06479239 | University of Virginia | Phase 1 / Phase 2 |
| Not Yet Recruiting | A PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss NCT06614751 | Danatlas Pharmaceuticals Co., Ltd | Phase 1 |
| Recruiting | CtDNA-guided Maintenance Therapy in Pancreatic Cancer NCT07054879 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | — |
| Recruiting | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors NCT06819215 | Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | Phase 1 / Phase 2 |
| Not Yet Recruiting | Anlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA NCT06621095 | RenJi Hospital | Phase 2 |
| Active Not Recruiting | Adebrelimab Combined With Irinotecan Liposomal (II), Oxaliplatin, and 5-FU/LV Conversion Therapy for Locally A NCT06766019 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Active Not Recruiting | Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Aden NCT06625320 | Revolution Medicines, Inc. | Phase 3 |
| Active Not Recruiting | MRD in PAAD Adjuvant Therapy NCT06867146 | Peking Union Medical College Hospital | N/A |
| Recruiting | Exploratory Platform Research on Precision Therapy of Advanced Pancreatic Cancer NCT06547736 | Fudan University | Phase 2 |
| Recruiting | Pancreatic Cancer Diagnosis With FAPI-PET Imaging NCT07098598 | Turku University Hospital | Phase 2 / Phase 3 |
| Recruiting | Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors NCT06617169 | Monopar Therapeutics | Phase 1 |
| Recruiting | AI-Assisted Non-Contrast CT for Multi-Cancer Screening NCT06632886 | Guo ShiWei | N/A |
| Recruiting | WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment NCT06291324 | Wake Forest University Health Sciences | — |
| Completed | Enhanced Assistance During Radiotherapy for Unmet Essential Needs NCT06582849 | Washington University School of Medicine | N/A |
| Recruiting | Profiling the Intratumoral Microbiome of Pancreatic Ductal Adenocarcinoma Based on EUS-FNB Tissue Samples and NCT06655233 | The Third Xiangya Hospital of Central South University | — |
| Recruiting | Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors NCT06843629 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | — |
| Recruiting | A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who I NCT05663515 | AstraZeneca | — |
| Recruiting | The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer. NCT06601010 | Ruijin Hospital | — |
| Not Yet Recruiting | The LINFU® U.S. Registry for the in the General Population Without Risk Factors NCT06276803 | Adenocyte, LLC | — |
| Recruiting | Evaluation, in Humans, of the Correlation Between Hepatotoxicity, Neurotoxicity Induced by Oxaliplatin, and Bl NCT06649474 | University Hospital, Clermont-Ferrand | N/A |
| Not Yet Recruiting | Liposomal Irinotecan in Combination With Oxaliplatin and S-1 Versus Gemcitabine Combined With Capecitabine as NCT06571461 | CSPC Ouyi Pharmaceutical Co., Ltd. | Phase 3 |
| Not Yet Recruiting | Irinotecan Liposome，Albumin Paclitaxel and Gemcitabine First-line Treatment for Pancreatic Cancer NCT06513455 | Harbin Medical University | Phase 1 / Phase 2 |
| Recruiting | Irinotecan Liposome in Combination With Capecitabine NCT06578052 | Junjie Hang | N/A |
| Recruiting | Oral Immunonutrition Therapy to Reduce Acute Toxicity After Neoadjuvant Chemoradiotherapy Pancreatic Cancer Pa NCT06736678 | Sun Yat-sen University | N/A |
| Active Not Recruiting | The Significance and Indications of Surgery for Synchronous Liver Metastatic Pancreatic Cancer NCT06873178 | China-Japan Friendship Hospital | — |
| Not Yet Recruiting | Research of the Application of Artificial Intelligence Model "PANDA" NCT06528223 | Zhejiang University | N/A |
| Active Not Recruiting | AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC NCT05632328 | Bruno Bockorny | Phase 2 |
| Recruiting | Adjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC) NCT06427447 | Changhai Hospital | Phase 3 |
| Recruiting | AI-powered Early Detection for Pancreatic Cancer Via Non-contrast CT in Opportunistic Screening Cohort NCT06638866 | Changhai Hospital | — |
| Recruiting | Characteristics of Intestinal Microbiome Following Pancreatic Surgery NCT06319755 | Royal Prince Alfred Hospital, Sydney, Australia | — |
| Recruiting | A New Strategy for Preoperative Drainage of Resectable Pancreatic Head Cancer Combined Severe Obstructive Jaun NCT06541340 | Ruijin Hospital | N/A |
| Recruiting | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer NCT06435260 | Hebei Medical University Fourth Hospital | Phase 2 |
| Recruiting | A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointes NCT06500052 | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors NCT06821048 | Weijia Fang, MD | Phase 1 |
| Recruiting | A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Soli NCT06440005 | Angiex, Inc. | Phase 1 |
| Recruiting | INSPIRE: a Multi-Cancer Early Detection Study NCT06440018 | Singlera Genomics Inc. | — |
| Recruiting | Clinical Study Evaluating the Effect of Losartan NCT06539806 | Tanta University | N/A |
| Recruiting | Ivonescimab(AK112/SMT112) in Combination With Stereotactic Body Radiation Therapy and Chemotherapy in Patients NCT06491472 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | IX001 TCR-T In the Treatment of Advanced Pancreatic Cancer and Colorectal Cancer Induced by KRAS Mutations NCT06487377 | Shanghai Pudong Hospital | Phase 1 |
| Recruiting | A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors NCT06465069 | Eli Lilly and Company | Phase 1 |
| Not Yet Recruiting | The LINFU® U.S. Registry in Patients With Clinical Signs and/or Symptoms of Disease NCT06276738 | Adenocyte, LLC | — |
| Recruiting | Multi-omics Model for Pancreatic Cancer Screening Using cfDNA NCT06456281 | Fudan University | — |
| Active Not Recruiting | Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2 NCT06384417 | Milton S. Hershey Medical Center | N/A |
| Recruiting | Intra-tumoral Mitazalimab (CD40 Antibody) With Irreversible Electroporation (IRE) in Locally Advanced Pancreas NCT06205849 | University of California, San Diego | Phase 1 |
| Recruiting | First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients NCT06313970 | Fudan University | Phase 2 |
| Recruiting | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors NCT06239194 | ModeX Therapeutics, An OPKO Health Company | Phase 1 / Phase 2 |
| Recruiting | Adebrelimab in Combination With NALIRIFOX in Locally Advanced Pancreatic Cancer NCT06475326 | Fudan University | Phase 2 |
| Recruiting | 99mTc Labeled FAP Targeted Molecular Probe in Early Diagnosis of Tumors NCT06438705 | Nanjing First Hospital, Nanjing Medical University | — |
| Recruiting | PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients NCT06359275 | Fudan University | Phase 2 |
| Not Yet Recruiting | Surufatinib Combined With Gemcitabine Plus Nab-paclitaxel in Locally Advanced Pancreatic Cancer NCT06361030 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 2 |
| Recruiting | Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors NCT06337084 | Monopar Therapeutics | Phase 1 |
| Recruiting | Exploratory Clinical Study of HRS-4642 Combined With Adebelimab in the Treatment of Advanced Pancreatic Cancer NCT06427239 | Fudan University | Phase 1 / Phase 2 |
| Completed | Correlation of Portal and Peripheral Venous ctDNA in Pancreatic Adenocarcinoma NCT06478056 | University Hospital, Rouen | N/A |
| Recruiting | A Study of JMT203 in Patients With Cancer Cachexia NCT06868849 | Shanghai JMT-Bio Inc. | Phase 1 |
| Recruiting | Central-boost Ablative Radiation Therapy for Solid Tumors (CBART) NCT06427460 | Changhai Hospital | Phase 2 |
| Unknown | Multimodal Imaging in Rectal Cancer & Pancreatic Cancer NCT06395337 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Unknown | Chemical Profiling of Colorectal and Pancreatic Cancers Using Breath Analysis - Feasibility Study NCT05400408 | Scentech Medical Technologies Ltd | N/A |
| Recruiting | Exploring the Impact of a Multi-modal Nutritional Intervention in Patients Undergoing Chemotherapy for Pancrea NCT06149546 | Cancer Trials Ireland | N/A |
| Enrolling By Invitation | Pancreatic Cancer Initial Detection Via Liquid Biopsy NCT06283576 | Karolinska University Hospital | — |
| Not Yet Recruiting | Oncolytic Virus Plus Anti-PD1 and Chemotherapy as Preoperative Therapy for Patients With BRPC/LAPC NCT06346808 | Sichuan University | Phase 1 |
| Not Yet Recruiting | EUS-guided CDS vs ERCP as First Line in Malignant Distal Obstruction in Borderline Disease (CARPEDIEM-2 Trial) NCT06375954 | Hospital Universitari de Bellvitge | N/A |
| Not Yet Recruiting | Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer NCT06409429 | Tianjin Medical University Cancer Institute and Hospital | Phase 2 / Phase 3 |
| Not Yet Recruiting | Newly Emerging Immunotherapy for Pancreatic Cancer Treatment NCT06370754 | Fudan University | Phase 1 / Phase 2 |
| Recruiting | A Phase I Clinical Study of QLC1101 in Patients With Advanced Solid Tumors NCT06403735 | Qilu Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | Gastrointestinal Microflora and Serum Metabolomics in Patients With Pancreatic Cancer and Chronic Pancreatitis NCT06411470 | Changhai Hospital | — |
| Recruiting | Treatment of Irinotecan Hydrochloride Liposome Injection II in China: a Real World Study of Pancreatic Cancer NCT06375473 | Peking Union Medical College Hospital | — |
| Not Yet Recruiting | A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cance NCT06233864 | Sun Yat-sen University | Phase 2 |
| Recruiting | Monitoring and Managing Glucose Levels in People With Pancreatic Cancer NCT05132244 | British Columbia Cancer Agency | N/A |
| Recruiting | Management of Malignant Gastric Outlet Obstruction Between Surgery and Endoscopy NCT06071507 | IRCCS San Raffaele | — |
| Completed | Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer NCT06378047 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Recruiting | Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer NCT06361316 | Kuirong Jiang | N/A |
| Completed | Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study NCT06323291 | H. Lee Moffitt Cancer Center and Research Institute | EARLY_Phase 1 |
| Not Yet Recruiting | Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer NCT05810792 | Sahlgrenska University Hospital | Phase 2 |
| Recruiting | mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemothe NCT06249321 | Fudan University | Phase 2 |
| Recruiting | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer NCT06326736 | Jinling Hospital, China | EARLY_Phase 1 |
| Recruiting | Mesopancreatic Excision for Pancreatic Duct Adenocarcinoma. NCT07148830 | Minia University | N/A |
| Not Yet Recruiting | Stereotactic Body Radiation Therapy Followed by NALIRIFOX vs NALIRIFOX for Borderline Resectable Pancreatic Ca NCT06259058 | Tianjin Medical University Cancer Institute and Hospital | Phase 1 / Phase 2 |
| Recruiting | Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer NCT06344156 | Sichuan University | Phase 1 |
| Unknown | Plasma Metabolic Biomarkers for Multi-Cancer Diagnosis NCT06363123 | Beijing Friendship Hospital | — |
| Terminated | Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in NCT06069778 | BioNTech SE | Phase 1 / Phase 2 |
| Recruiting | EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope NCT06340620 | Orlando Health, Inc. | N/A |
| Active Not Recruiting | Phase 2 Study of TTX-030 and Chemotherapy With or Without Budigalimab for 1L mPDAC Patients NCT06119217 | Trishula Therapeutics, Inc. | Phase 2 |
| Recruiting | Examining Safety, Efficacy and Feasibility of Preoperative Propranolol in Patients With PDAC. NCT06145074 | Zealand University Hospital | Phase 2 |
| Not Yet Recruiting | Clinical Trial Evaluating Low Dose G-FLIP Plus Mitomycin C for Stage IV Pancreatic Cancer NCT06233877 | Hirschfeld Oncology | Phase 2 |
| Unknown | Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (M NCT05872867 | Wellmarker Bio | Phase 1 |
| Active Not Recruiting | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors NCT06334432 | Nuvation Bio Inc. | Phase 1 / Phase 2 |
| Recruiting | XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cance NCT06353646 | Wu Wenming | N/A |
| Active Not Recruiting | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors NCT06238479 | Eli Lilly and Company | Phase 1 |
| Unknown | Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors NCT06256055 | UTC Therapeutics Inc. | Phase 1 |
| Unknown | Graphic Novel for Patients Undergoing EUS-FNB NCT06268106 | The Mediterranean Institute for Transplantation and Advanced Specialized Therapies | N/A |
| Recruiting | The Effect of Probiotics ATG-F4 in Cancer Patients NCT06436976 | Chungnam National University Hospital | Phase 2 |
| Recruiting | Transcatheter Arterial Infusion to Patients With Advanced Pancreatic Cancer NCT06196788 | Fudan University | Phase 2 |
| Active Not Recruiting | A Study to Test Different Doses of BI 765049 Alone and in Combination With Ezabenlimab in Asian People With Ad NCT06091930 | Boehringer Ingelheim | Phase 1 |
| Recruiting | A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors NCT06244771 | Frontier Medicines Corporation | Phase 1 / Phase 2 |
| Recruiting | Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer NCT06423963 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Not Yet Recruiting | HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cance NCT06217042 | Fudan University | Phase 3 |
| Withdrawn | Mesothelin-targeted CAR-T Cells as a Neo-adjuvant Treatment in Patients With Resectable Pancreatic Cancers: a NCT06054308 | Chinese University of Hong Kong | N/A |
| Not Yet Recruiting | Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Pati NCT06234072 | Shenzhen University General Hospital | Phase 2 |
| Not Yet Recruiting | Perioperative Treatment in High-risk Resectable Pancreatic Cancer With NALIRIFOX NCT06210360 | Changhai Hospital | Phase 2 |
| Unknown | Phase II Study of Concurrent Radiotherapy With Envafolimab and Capecitabine in LAPC NCT06202014 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 |
| Recruiting | A Study of Trilaciclib Combined With mFOLFIRINOX in the Treatment of Patients With Advanced Pancreatic Cancer NCT06151262 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Recruiting | Artificial Intelligence in Endoscopic Ultrasound NCT06564571 | Orlando Health, Inc. | — |
| Active Not Recruiting | Radiotherapy in Combination With TTI-101 in Borderline Resectable and Locally Advanced Pancreatic Ductal Adeno NCT06141031 | Washington University School of Medicine | Phase 1 |
| Recruiting | Liquid Biopsy (ctDNA) Guided Treatment in Localized Pancreatic Cancer: Neoadjuvant CTX vs. Upfront Surgery NCT06391892 | Elisabethinen Hospital | Phase 3 |
| Recruiting | MicroEnvironment Tumor Effects of Radiotherapy - Comprehensive Radiobiology Assessment TRial NCT05975593 | Washington University School of Medicine | N/A |
| Active Not Recruiting | Evaluation of an Early Radiomic Signature in Patients With Metastatic Pancreatic Adenocarcinoma Treated With F NCT07243288 | Assistance Publique - Hôpitaux de Paris | — |
| Recruiting | Effectiveness of the Transversus Abdominis Plane Block Associated With Opioid Spinal Anesthesia on Analgesia A NCT06499792 | University Hospital, Strasbourg, France | — |
| Completed | Multivisceral Oncological Resections Involving the Pancreas - An International Multicenter Study NCT07091097 | Martin-Luther-Universität Halle-Wittenberg | — |
| Not Yet Recruiting | Early Phase I Study of Autologous T Cells (EX02 CAR-T) for Unresectable Pancreatic/Bile Duct Cancer NCT06196658 | Zhang Xiaofeng,MD | EARLY_Phase 1 |
| Recruiting | Bile Omics for Diagnosing Indeterminate Biliary Strictures NCT07007832 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Not Yet Recruiting | Study of Personalized Tumour Vaccines and a PD-L1 Blocker in Patients With Surgically Resected Pancreatic Aden NCT06156267 | Fudan University | EARLY_Phase 1 |
| Unknown | Cadonilimab Plus mFOLFIRINOX as Conversion Therapy in LAPC NCT06153368 | The First Affiliated Hospital with Nanjing Medical University | Phase 2 |
| Terminated | Study of IK-595 in RAS- or RAF-altered Advanced Tumors NCT06270082 | Ikena Oncology | Phase 1 |
| Recruiting | A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection NCT06166147 | Fudan University | — |
| Active Not Recruiting | A Study of Glipizide to Treat High Blood Sugar in People With Pancreatic Cancer NCT06168812 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer NCT06134765 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 |
| Recruiting | Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals NCT06122896 | Dana-Farber Cancer Institute | EARLY_Phase 1 |
| Active Not Recruiting | ZN-c3 + Gemcitabine in Pancreatic Cancer NCT06015659 | Brandon Huffman, MD | Phase 2 |
| Not Yet Recruiting | NKG2D/CLDN18.21 CAR-T(KD-496) in the Treatment of Advanced NKG2DL+/CLDN18.2+ Solid Tumor NCT06134960 | Peking University | Phase 1 |
| Active Not Recruiting | A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer NCT05604560 | Lei Zheng | Phase 2 |
| Completed | Quality of Life in Elderly Patients After Pancreatic Cancer Surgery NCT06079229 | Hospices Civils de Lyon | — |
| Recruiting | Early-stage Detection of LIver, Biliary TRAct and PancReatic Cancers NCT06139042 | Second Affiliated Hospital, School of Medicine, Zhejiang University | — |
| Completed | Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 ( NCT06129422 | Nihon Medi-Physics Co., Ltd. | Phase 1 |
| Recruiting | A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tum NCT06008288 | Allist Pharmaceuticals, Inc. | Phase 2 |
| Recruiting | Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer NCT06389760 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Phase 2 |
| Recruiting | Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the NCT05922930 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer W NCT06307080 | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | N/A |
| Unknown | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy NCT06342323 | Peking University Third Hospital | — |
| Not Yet Recruiting | Canagliflozin With Gemcitabine in Pancreatic Carcinoma NCT05903703 | Zhang Xiaofeng,MD | N/A |
| Recruiting | REVOLUTION Surgery (REVOLUTION Surgery) NCT05642819 | University of Edinburgh | — |
| Recruiting | A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Thera NCT05989724 | Qurgen Inc. | Phase 1 |
| Active Not Recruiting | The MONITOR Study: Remote Monitoring Of a Nutrition Intervention To Optimize Treatment Response NCT06050395 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Active Not Recruiting | Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring NCT05919537 | Hummingbird Bioscience | Phase 1 |
| Unknown | The Application of Probe Confocal Laser Endomicroscopy in Pancreatic Tumor Surgery NCT06289803 | Fudan University | N/A |
| Unknown | Cross-sectional Survey on Palliative Therapy for Pancreatic Cancer Patient NCT06090825 | Peking Union Medical College Hospital | — |
| Enrolling By Invitation | NON-INVASIVE BLOOD FLOW ASSESSMENT: Computational Tool for Measuring Arterial Flow From CT NCT07155616 | Hospital Clinic of Barcelona | — |
| Unknown | Venous Thromboembolism in Primary Pancreatic Tumour Resection NCT05964621 | University of Thessaly | — |
| Recruiting | A Feasibility and Safety Study of Intratumoral Diffusing Alpha Radiation Emitters for the Treatment of Advance NCT05657743 | Alpha Tau Medical LTD. | N/A |
| Unknown | Hyperthermia Treatment Added to Chemotherapy Standard of Care for Pancreatic Tumors NCT05959395 | NeoTherma Oncology | N/A |
| Recruiting | Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS) NCT06001268 | H. Lee Moffitt Cancer Center and Research Institute | N/A |
| Completed | Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America NCT05924789 | Latin American Cooperative Oncology Group | — |
| Recruiting | A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue NCT05837767 | Memorial Sloan Kettering Cancer Center | N/A |
| Completed | Ketamine-midazolam as a Sedative Agent in Endoscopic Retrograde Cholangiopancreatography. NCT06111872 | National University of Malaysia | Phase 2 |
| Active Not Recruiting | Tele-PancFit: A Multi-site Trial of Video-based Strengthening Exercise Prehabilitation for Patients With Resec NCT05836870 | M.D. Anderson Cancer Center | Phase 3 |
| Recruiting | Prehabilitation in Pancreatic Surgery NCT06069297 | IRCCS San Raffaele | N/A |
| Active Not Recruiting | A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With NCT05984602 | NYU Langone Health | Phase 1 |
| Active Not Recruiting | Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors NCT05945823 | Taiho Oncology, Inc. | Phase 2 |
| Recruiting | A Study to Evaluate the Efficacy and Safety of CT041 After Adjuvant Chemotherapy for Pancreatic Cancer NCT05911217 | CARsgen Therapeutics Co., Ltd. | Phase 1 |
| Recruiting | Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatop NCT05451043 | AHS Cancer Control Alberta | Phase 2 |
| Not Yet Recruiting | Locally Advanced Pancreatic Cancer Treated With ABLAtivE Stereotactic MRI-guided Adaptive Radiation Therapy NCT05585554 | Viewray Inc. | N/A |
| Completed | Cohort Study on Nutritional, Metabolic, and Volumetric Assessment After Pancreaticoduodenectomy NCT07159672 | Marco Aurélio Ribeiro, PhD | — |
| Recruiting | CTS2190 Phase I /II Clinical Study in Patients NCT06224387 | CytosinLab Therapeutics Co., Ltd. | Phase 1 / Phase 2 |
| Unknown | SBRT Plus vNKT for Pancreatic Cancer NCT05783076 | Changhai Hospital | Phase 2 |
| Withdrawn | GEM+Nab-Paclitaxel Plus Losartan Followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer NCT05861336 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | Phase 2 |
| Recruiting | Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer NCT05776524 | THERABIONIC INC. | Phase 2 |
| Recruiting | A Study of Hansoh (HS)-10502 in Patients With Advanced Solid Tumors NCT05740956 | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Phase 1 |
| Recruiting | First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic C NCT05141149 | Prestige Biopharma Limited | Phase 1 / Phase 2 |
| Not Yet Recruiting | A Multicenter Prospective Randomized Controlled Study of RPD Versus LPD NCT05755607 | The First Affiliated Hospital of University of South China | N/A |
| Unknown | A Prospective Clinical Study Using an Artery-first Intermediate Approach in Robot-assisted Pancreaticoduodenec NCT05660915 | The First Affiliated Hospital of University of South China | N/A |
| Completed | Sequential Nutrition Intervention for Pancreatic Cancer Patients Undergoing CyberKnife Radiotherapy NCT07057843 | The First Hospital of Hebei Medical University | N/A |
| Recruiting | TCR-T Cell Therapy on Advanced Solid Tumors NCT05438667 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | EARLY_Phase 1 |
| Not Yet Recruiting | A Prospective Study on the Safety and Efficacy of Robot-assisted Pancreaticoduodenectomy NCT05755594 | The First Affiliated Hospital of University of South China | N/A |
| Active Not Recruiting | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid NCT05864144 | Sensei Biotherapeutics, Inc. | Phase 1 / Phase 2 |